アブストラクト
Japanese
| Title | 多発性硬化症・視神経脊髄炎の分子標的治療 |
|---|---|
| Subtitle | 第37回日本神経治療学会総会特集1 シンポジウム7 : 免疫性神経疾患診療の最前線 - 1 |
| Authors | 中島一郎** |
| Authors (kana) | |
| Organization | **東北医科薬科大学医学部老年神経内科学 |
| Journal | 神経治療学 |
| Volume | 37 |
| Number | 3 |
| Page | 407-410 |
| Year/Month | 2020 / |
| Article | 報告 |
| Publisher | 日本神経治療学会 |
| Abstract | 「はじめに」 多発性硬化症(multiple sclerosis : MS)と視神経脊髄炎(neuromyelitis optica : NMO)はいずれも中枢神経の炎症性疾患であり, 再発と寛解を繰り返すのが特徴である. 再発に対しては副腎皮質ステロイド剤による急性期治療が有用であるが, MSの再発予防や進行抑制にはステロイド剤は無効である. 従来, MSの再発予防にはinterferon-betaやglatiramer酢酸塩が用いられてきたが, これらは免疫調整剤であって, 特定の分子を標的にしたものではなかった. そのため, 効果が一様ではなく, ノンレスポンダーも数多く存在した. スフィンゴシン1-リン酸(sphingosine-1-phosphate : S1P1)受容体に作用するfingolimodは, 当初免疫抑制薬としての活性に注目されて開発され, S1P受容体に特異的に作用することが明らかになったのはその作用機序を検証してからである. |
| Practice | 臨床医学：内科系 |
| Keywords | multiple sclerosis, neuromyelitis optica, monoclonal antibody, disease modifying therapy, clinical trial |
English
| Title | Molecular targeted therapy for multiple sclerosis and neuromyelitis optica |
|---|---|
| Subtitle | |
| Authors | Ichiro NAKASHIMA |
| Authors (kana) | |
| Organization | Department of Neurology, Tohoku Medical and Pharmaceutical University |
| Journal | Neurological Therapeutics |
| Volume | 37 |
| Number | 3 |
| Page | 407-410 |
| Year/Month | 2020 / |
| Article | Report |
| Publisher | Japanese Society of Neurological Therapeutics |
| Abstract | Molecular targeted therapy including monoclonal antibody therapy is a new treatment strategy for demyelinating diseases such as multiple sclerosis (MS) and neuromyelitis optica (NMO). In Japan, only fingolimod and natalizumab are currently approved for treatment in MS. A novel S1P receptor modulator and a monoclonal antibody targeting CD20 are willing to be approved soon. In NMO, several monoclonal antibodies are waiting for the approval in Japan. Although either drug has a strong effect to prevent relapses in NMO, the indication should be considered by their high costs. In this review, I summarize the characteristics of each molecular targeted therapy. |
| Practice | Clinical internal medicine |
| Keywords | multiple sclerosis, neuromyelitis optica, monoclonal antibody, disease modifying therapy, clinical trial |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Kappos L, Radue EW, O'Connor P et al : A placebo-control-led trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362 : 387-401, 2010
- 2) Polman CH, O'Connor PW, Havrdova E et al : A randomized, placebo-controlled trial of natalizumab for relapsing multi-ple sclerosis. N Engl J Med 354 : 899-910, 2006
- 3) Rudick RA, Stuart WH, Calabresi PA et al : Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354 : 911-923, 2006
- 4) Montalban X, Hauser SL, Kappos L et al : Ocrelizumab ver-sus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 376 : 209-220, 2017
- 5) 田中良哉 : 自己免疫疾患の治療薬開発 病態の多様性を見据えて 抗CD20抗体による自己免疫疾患の治療 基礎から臨床での新展開まで. 薬誌 129 : 675-679, 2009
残りの10件を表示する
- 6) Cree BA, Lamb S, Morgan K et al : An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64 : 1270-1272, 2005
- 7) Kim SH, Jeong IH, Hyun JW et al : Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica : Influence of FCGR3A Polymorphisms on the Therapeutic Re-sponse to Rituximab. JAMA Neurol 72 : 989-995, 2015
- 8) 田原将行 : 視神経脊髄炎の再発に対するリツキシマブの有用性を検証する第II/III相多施設共同プラセボ対照無作為化試験. 臨評価 43 : 414-417, 2016
- 9) Akaishi T, Nakashima I : Efficiency of antibody therapy in demyelinating diseases. Int Immunol 29 : 327-335, 2017
- 10) Paul F, Murphy O, Pardo S et al : Investigational drugs in development to prevent neuromyelitis optica relapses. Ex-pert Opin Investig Drugs 27 : 265-271, 2018
- 11) Collongues N, Ayme-Dietrich E, Monassier L et al : Pharma-cotherapy for Neuromyelitis Optica Spectrum Disorders : Current Management and Future Options. Drugs 79 : 125-142, 2019
- 12) Pittock SJ, Berthele A, Fujihara K et al : Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disor-der. N Engl J Med, 2019
- 13) Yamamura T, Kleiter I, Fujihara K et al : Efficacy of satrali-zumab(SA237) in subgroups of patients in SAkuraSky : a Phase III double-blind, placebo-controlled, add-on study in patients with neuromyelitis optica spectrum disorder(NMOSD)(S43. 008). Neurology 92 : S43. 008, 2019
- 14) Igawa T, Mimoto F, Hattori K : pH-dependent antigen-bind-ing antibodies as a novel therapeutic modality. Biochim Bio-phys Acta 1844 : 1943-1950, 2014
- 15) Cree BAC, Bennett JL, Kim HJ et al : Inebilizumab for the treatment of neuromyelitis optica spectrum disorder(N-MO-mentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 394 : 1352-1363, 2019
